307 related articles for article (PubMed ID: 24744577)
1. Current and future molecular diagnostics in colorectal cancer and colorectal adenoma.
Tsang AH; Cheng KH; Wong AS; Ng SS; Ma BB; Chan CM; Tsui NB; Chan LW; Yung BY; Wong SC
World J Gastroenterol; 2014 Apr; 20(14):3847-57. PubMed ID: 24744577
[TBL] [Abstract][Full Text] [Related]
2. Comparative effectiveness of screening strategies for colorectal cancer.
Barzi A; Lenz HJ; Quinn DI; Sadeghi S
Cancer; 2017 May; 123(9):1516-1527. PubMed ID: 28117881
[TBL] [Abstract][Full Text] [Related]
3. Noninvasive molecular biomarkers for the detection of colorectal cancer.
Kim HJ; Yu MH; Kim H; Byun J; Lee C
BMB Rep; 2008 Oct; 41(10):685-92. PubMed ID: 18959813
[TBL] [Abstract][Full Text] [Related]
4. Colorectal Cancer Screening: Recommendations for Physicians and Patients From the U.S. Multi-Society Task Force on Colorectal Cancer.
Rex DK; Boland CR; Dominitz JA; Giardiello FM; Johnson DA; Kaltenbach T; Levin TR; Lieberman D; Robertson DJ
Gastroenterology; 2017 Jul; 153(1):307-323. PubMed ID: 28600072
[TBL] [Abstract][Full Text] [Related]
5. Fecal occult blood test for colorectal cancer screening: an evidence-based analysis.
Medical Advisory Secretariat
Ont Health Technol Assess Ser; 2009; 9(10):1-40. PubMed ID: 23074514
[TBL] [Abstract][Full Text] [Related]
6. Detection of aberrant methylation in fecal DNA as a molecular screening tool for colorectal cancer and precancerous lesions.
Huang ZH; Li LH; Yang F; Wang JF
World J Gastroenterol; 2007 Feb; 13(6):950-4. PubMed ID: 17352030
[TBL] [Abstract][Full Text] [Related]
7. Combined Plasma MicroRNA and Fecal Occult Blood Tests in Early Detection of Colorectal Cancer.
Luo X; Wu Y; Ji M; Zhang S
Clin Lab; 2019 May; 65(5):. PubMed ID: 31115212
[TBL] [Abstract][Full Text] [Related]
8. Familial colorectal cancer screening: When and what to do?
Del Vecchio Blanco G; Paoluzi OA; Sileri P; Rossi P; Sica G; Pallone F
World J Gastroenterol; 2015 Jul; 21(26):7944-53. PubMed ID: 26185367
[TBL] [Abstract][Full Text] [Related]
9. Screening for Colorectal Cancer: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force.
Lin JS; Piper MA; Perdue LA; Rutter CM; Webber EM; O'Connor E; Smith N; Whitlock EP
JAMA; 2016 Jun; 315(23):2576-94. PubMed ID: 27305422
[TBL] [Abstract][Full Text] [Related]
10. [Chemical or immunological tests for the detection of fecal occult blood in colorectal cancer screening?].
Quintero E
Gastroenterol Hepatol; 2009 Oct; 32(8):565-76. PubMed ID: 19577340
[TBL] [Abstract][Full Text] [Related]
11. Current status of screening for colorectal cancer.
Garborg K; Holme Ø; Løberg M; Kalager M; Adami HO; Bretthauer M
Ann Oncol; 2013 Aug; 24(8):1963-72. PubMed ID: 23619033
[TBL] [Abstract][Full Text] [Related]
12. Clinical Practice Guideline on Screening for Colorectal Cancer in Individuals With a Family History of Nonhereditary Colorectal Cancer or Adenoma: The Canadian Association of Gastroenterology Banff Consensus.
Leddin D; Lieberman DA; Tse F; Barkun AN; Abou-Setta AM; Marshall JK; Samadder NJ; Singh H; Telford JJ; Tinmouth J; Wilkinson AN; Leontiadis GI
Gastroenterology; 2018 Nov; 155(5):1325-1347.e3. PubMed ID: 30121253
[TBL] [Abstract][Full Text] [Related]
13. Analysis of the effectiveness of two noninvasive fecal tests used to screen for colorectal cancer in average-risk adults.
Sharma T
Public Health; 2020 May; 182():70-76. PubMed ID: 32179290
[TBL] [Abstract][Full Text] [Related]
14. Colorectal cancer: from prevention to personalized medicine.
Binefa G; Rodríguez-Moranta F; Teule A; Medina-Hayas M
World J Gastroenterol; 2014 Jun; 20(22):6786-808. PubMed ID: 24944469
[TBL] [Abstract][Full Text] [Related]
15. Identification and Validation of MicroRNA Profiles in Fecal Samples for Detection of Colorectal Cancer.
Duran-Sanchon S; Moreno L; Augé JM; Serra-Burriel M; Cuatrecasas M; Moreira L; Martín A; Serradesanferm A; Pozo À; Costa R; Lacy A; Pellisé M; Lozano JJ; Gironella M; Castells A
Gastroenterology; 2020 Mar; 158(4):947-957.e4. PubMed ID: 31622624
[TBL] [Abstract][Full Text] [Related]
16. The compliance rate for the second diagnostic evaluation after a positive fecal occult blood test: A systematic review and meta-analysis.
Gingold-Belfer R; Leibovitzh H; Boltin D; Issa N; Tsadok Perets T; Dickman R; Niv Y
United European Gastroenterol J; 2019 Apr; 7(3):424-448. PubMed ID: 31019712
[TBL] [Abstract][Full Text] [Related]
17. Novel molecular screening approaches in colorectal cancer.
Miller S; Steele S
J Surg Oncol; 2012 Apr; 105(5):459-67. PubMed ID: 22441897
[TBL] [Abstract][Full Text] [Related]
18. Colorectal cancer detection in an asymptomatic population: fecal immunochemical test for hemoglobin vs. fecal M2-type pyruvate kinase.
Caviglia GP; Cabianca L; Fagoonee S; Gili FM
Biochem Med (Zagreb); 2016; 26(1):114-20. PubMed ID: 26981025
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of Fecal M2PK as a Diagnostic Marker in Colorectal Cancer.
Dabbous HK; Mohamed YAE; El-Folly RF; El-Talkawy MD; Seddik HE; Johar D; Sarhan MA
J Gastrointest Cancer; 2019 Sep; 50(3):442-450. PubMed ID: 29626277
[TBL] [Abstract][Full Text] [Related]
20. DIAGNOSTIC ACCURACY OF ONE SAMPLE OR TWO SAMPLES QUANTITATIVE FECAL IMMUNOCHEMICAL TESTS FOR INTESTINAL NEOPLASIA DETECTION.
Mattar R; Marques SB; Minata MK; Silva-Etto JMKD; Sakai P; DE Moura EGH
Arq Gastroenterol; 2020; 57(3):316-322. PubMed ID: 32935747
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
